Epinastine

ArtNr	HY-B0640-500mg
Hersteller	MedChem Express
CAS-Nr.	80012-43-7
Menge	500 mg
Quantity options	100 mg 10 mM/1 mL 500 mg 50 mg
Kategorie	Oncology Food Safety Histamines Neuroscience Neuroinflammation Metabolism Diabetes Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer
Typ	Inhibitors
Specific against	other
Purity	98.0
Citations	[1]C Kamei, et al. Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: (I). Elucidation of the mechanism for histamine release inhibition. Immunopharmacol Immunotoxicol. 1992;14(1-2):191-205.\|[2]T Roeder, et al. Epinastine, a highly specific antagonist of insect neuronal octopamine receptors. ur J Pharmacol. 1998 May 22;349(2-3):171-7. \|[3]T Kohyama, et al. A novel antiallergic drug epinastine inhibits IL-8 release from human eosinophils. Biochem Biophys Res Commun. 1997 Jan 3;230(1):125-8.\|[4]Nakagawa T, et al. Modulatory effects of epinastine hydrochloride on IL-4 mRNA expression by peripheral blood mononuclear cells. Int Arch Allergy Immunol. 1997 May-Jul;113(1-3):321-2. \|[5]Hanashiro K, et al. Antiallergic drugs, azelastine hydrochloride and epinastine hydrochloride, inhibit ongoing IgE secretion of rat IgE-producing hybridoma FE-3 cells. Eur J Pharmacol. 2006 Oct 10;547(1-3):174-83. \|[6]Kanai K, et al. Suppressive activity of epinastine hydrochloride on TARC production from human peripheral blood CD4+ T cells in-vitro. J Pharm Pharmacol. 2005 Aug;57(8):1027-36. \|[7]Inagaki N, et al. Evaluation of anti-scratch properties of oxatomide and epinastine in mice. Eur J Pharmacol. 2000 Jul 14;400(1):73-9. \|[8]Zhang X, et al. Identification of Epinastine as CD96/PVR inhibitor for cancer immunotherapy. BMC Biol. 2025 Jan 27;23(1):27.
Smiles	NC1=NCC2N1C3=CC=CC=C3CC4=CC=CC=C24
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	WAL801
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Category	Reference compound / Active compounds; API
Manufacturer - Targets	Histamine Receptor; Interleukin Related; Transmembrane Glycoprotein
Manufacturer - HS Code	H302, H319, H372, H410
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, protect from light, stored under nitrogen)
Molecular Weight	249317
Product Description	Epinastine (WAL801) is a selective and orally active histamine H1 receptor antagonist, CD96/PVR inhibitor and mast cell stabilizer. Epinastine has high affinity for neuronal octopamine receptors in locusts (Ki = 2 nM) and honeybees (Ki = 1.1 nM). Epinastine hydrochloride inhibits TARC, IL-8, and IL-4. Epinastine activates anti-colon cancer immunity and inhibits Substance P (HY-P0201)-induced scratching behavior and increased vascular permeability. Epinastine can be used in the research of allergic diseases[1][2][3][4][5][6][7][8].
Manufacturer - Research Area	Cancer; Inflammation/Immunology; Neurological Disease; Cardiovascular Disease
Solubility	DMSO : ≥ 50 mg/mL\|H2O : < 0.1 mg/mL (ultrasonic)
Manufacturer - Pathway	GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling
Clinical information	Launched
Isoform	H1 Receptor; IL-4; IL-8
UNSPSC Code	12352005
Precautionary	H302, H319, H372, H410

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.